Country: Canada
Language: English
Source: Health Canada
METOPROLOL TARTRATE
JUNO PHARMACEUTICALS CORP.
C07AB02
METOPROLOL
1MG
SOLUTION
METOPROLOL TARTRATE 1MG
INTRAVENOUS
10X5ML
Prescription
BETA-ADRENERGIC BLOCKING AGENTS
Active ingredient group (AIG) number: 0111923004; AHFS:
APPROVED
2020-04-16
_Metoprolol Tartrate Injection USP Page 1 of 38 _ PRODUCT MONOGRAPH PR METOPROLOL TARTRATE INJECTION USP (metoprolol tartrate) 5 mL vials (1 mg / mL) Sterile Solution β-Adrenergic Receptor Blocking Agent Juno Pharmaceuticals Corp. 402-2233 Argentia Road Mississauga, Ontario L5N 2X7 Date of Revision: July 05, 2023 M Submission Control No: 271006 _Metoprolol Tartrate Injection USP Page 2 of 38 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ............................................................ 3 SUMMARY PRODUCT INFORMATION .......................................................................... 3 INDICATIONS AND CLINICAL USE ................................................................................ 3 CONTRAINDICATIONS ..................................................................................................... 4 WARNINGS AND PRECAUTIONS .................................................................................... 4 ADVERSE REACTIONS .................................................................................................... 10 DRUG INTERACTIONS .................................................................................................... 12 DOSAGE AND ADMINISTRATION ................................................................................ 18 OVERDOSAGE .................................................................................................................. 20 ACTION AND CLINICAL PHARMACOLOGY .............................................................. 21 STORAGE AND STABILITY ............................................................................................ 24 SPECIAL HANDLING INSTRUCTIONS ......................................................................... 24 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................... 25 PART II: SCIENTIFIC INFORMATION ................................................................................. 26 PHARMACEUTICAL INFORMATION .................................... Read the complete document